Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 7/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455670 | 1.00 | — | — | |
| SCHEMBL29320 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| Dodecyl Methyl Sulfoxide SCHEMBL313076 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL29144 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL7864589 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL221373 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL5074212 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL224939 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL8587009 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL5294900 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 931 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021057-A1 | TRANSDERMAL DEVICE COMPRISING PRODRUG MOLECULES AND METHODS OF USING THE SAME | Remedy Diagnostics LLC (US) | 2026-01-22 | — | — | US | claimed |
| CN-117858621-A | Synergistic effect between isothiocyanate and mixture of commercial fungicides | 农维股份公司 | 2024-04-09 | — | — | CN | claimed |
| US-11654103-B2 | Skin care formulation | EMBRYOGENESIS PTY LTD | 2023-05-23 | — | — | US | claimed |
| US-20230052698-A1 | TRANSDERMAL DEVICE COMPRISING IBUPROFEN PRODRUG MOLECULES | Remedy Diagnostics LLC (US) | 2023-02-16 | — | — | US | claimed |
| CN-113512196-B | Alcohol solution of alkyl silanol and preparation method | 中交上海三航科学研究院有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-4021427-A1 | TRANSDERMAL DEVICE COMPRISING PAIN MOLECULES | Remedy Diagnostics LLC (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114681391-A | Pharmaceutical product comprising a ROR gamma modulator | 江苏恒瑞医药股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20220087949-A1 | TRANSDERMAL DEVICE COMPRISING IBUPROFEN PRODRUG MOLECULES | Remedy Diagnostics LLC (US) | 2022-03-24 | — | — | US | claimed |
| US-20210330579-A1 | SKIN CARE FORMULATION | EMBRYOGENESIS PTY LTD (AU) | 2021-10-28 | — | — | US | claimed |
| US-20210322299-A1 | SKIN CARE FORMULATION | EMBRYOGENESIS PTY LTD (AU) | 2021-10-21 | — | — | US | claimed |
| US-4150114-A | ENHANCED PENETRATION | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-17 | — | — | US | claimed |
| US-4148893-A | SUGAR ESTER AND DIALKYL SULFOXIDE ENHANCE PENETRATION THROUGH SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148887-A | SUGAR ESTER WITH A METHYL SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148917-A | PENETRATION | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148874-A | ENHANCE PENETRATION OF PHARMOCOLOGICALLY ACTIVE AGENTS THROUGH THE SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148924-A | Dermatological compositions | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4130643-A | STEROID, SUCROSE ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1978-12-19 | — | — | US | claimed |
| US-4018932-A | 2,3,5,6-TETRAHYDRO-IMIDAZO (2,1-6) THIAZOLE | AMERICAN CYANAMID COMPANY (US) | 1977-04-19 | — | — | US | claimed |
| US-3953599-A | ANTICHOLINERGIC SCOPOLAMINE ESTERS | THE PROCTER & GAMBLE COMPANY (US) | 1976-04-27 | — | — | US | claimed |
| US-3952099-A | MICROBIOCIDE, SUGAR ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-04-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021057-A1 | TRANSDERMAL DEVICE COMPRISING PRODRUG MOLECULES AND METHODS OF USING THE SAME | CYP2D6, CYP2C9, CYP2E1 | TSHR 3842/4885THRB 1588/4885CES2 1307/4885 |
| US-20230052698-A1 | TRANSDERMAL DEVICE COMPRISING IBUPROFEN PRODRUG MOLECULES | PTGES, PTGES2, PTGES3 | TSHR 3191/4885THRB 1589/4885CES2 1366/4885 |
| US-20220087949-A1 | TRANSDERMAL DEVICE COMPRISING IBUPROFEN PRODRUG MOLECULES | PTGES, PTGES2, PTGES3 | TSHR 3191/4885THRB 1589/4885CES2 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.